Intarcia Announces Positive Phase 3 Data For ITCA 650 In Patients with Type 2 Diabetes
News, Type 2 Diabetes News
Intarcia Therapeutics, Inc. an emerging biopharmaceutical company developing therapies that combine medicine with technology, recently announced positive data from its FREEDOM-2 study, a 52-week Phase 3 clinical trial that aimed to ... Read more